Table 4.
Measures of effectiveness
| Measure | Baseline, mean (SD) | Patients evaluated at baseline (n) | Week 4, mean (SD)a | Patients evaluated at week 4 (n) | Week 24, mean (SD)a | Patients evaluated at week 24 (n) |
|---|---|---|---|---|---|---|
| DAS28 | 5.9 (1.2) | 8902 | 4.3 (1.3) | 4754 | 3.8 (1.3) | 8137 |
| Duration of morning stiffness (min) | 111.3 (181.3) | 5858 | 44.2 (114.0) | 3201 | 31.1 (90.1) | 5058 |
| Tender joints (n) | 9.2 (7.0) | 12727 | 4.2 (4.8) | 7873 | 3.0 (4.1) | 12321 |
| Swollen joints (n) | 8.6 (6.2) | 12727 | 4.1 (4.3) | 7871 | 2.8 (3.6) | 12319 |
| General health status (patient visual analog scale) (mm) | 60.1 (22.7) | 11535 | 36.6 (22.5) | 6702 | 30.7 (22.1) | 10616 |
| ESR (mm/h) | 58.7 (33.0) | 9719 | 38.1 (27.7) | 5732 | 34.8 (27.5) | 9484 |
| CRP (mg/dL) | 3.6 (3.3) | 12693 | 1.4 (2.1) | 8298 | 1.2 (2.0) | 12770 |
CRP C-reactive protein, DAS28 modified disease activity score including a 28-joint count, ESR erythrocyte sedimentation rate
aAll comparisons differed significantly (p < 0.01 vs. baseline), by t-test